HSP90AA1 and pancreatic neoplasm: Data suggest that the binding of EGCG to Hsp90 impairs the association of Hsp90 with its co-chaperones, thereby inducing the degradation of Hsp90 client proteins, resulting in anti-proliferating effects in pancreatic cancer cells [76].